Table 1.
Characteristics of Fully Vaccinated Persons and Covid-19 Cases and Deaths for 15 U.S. Jurisdictions, from January 3 to September 4, 2021
| Covid-19 cases | Covid-19 deaths | |||||
|---|---|---|---|---|---|---|
| Characteristic | No. of total vaccinated for 15 jurisdictions | No. of cases | Case rate per 100,000 person-wk* | No. of total vaccinated for 14 jurisdictions | No. ofdeaths | Death rate per 100,000 person-wk* |
| Overall | 48,832,299 | 411,661 | 46.7 (46.6–46.9) | 45,988,351 | 6322 | 0.76 (0.75–0.78) |
| Age — yr | ||||||
| 12–17 | 2,253,130 | 8974 | 39.3 (38.5–40.1) | 2,119,998 | 1 | 0 (0–0.03)† |
| 18–49 | 20,022,549 | 189,269 | 57.5 (57.2–57.7) | 18,907,371 | 134 | 0.04 (0.04–0.05) |
| 50–64 | 12,853,359 | 103,496 | 44.9 (44.6–45.2) | 12,099,120 | 741 | 0.34 (0.32–0.37) |
| 65–79 | 10,614,732 | 80,666 | 35.4 (35.1–35.6) | 9,971,402 | 2371 | 1.11 (1.06–1.15) |
| ≥80 | 3,088,529 | 29,256 | 41.9 (41.4–42.4) | 2,890,460 | 3075 | 4.71 (4.55–4.88) |
| Vaccine product | ||||||
| BNT162b2 (Pfizer-BioNTech) | 26,269,165 | 247,051 | 53.1 (52.9–53.3) | 24,766,315 | 3701 | 0.85 (0.82–0.87) |
| mRNA-1273 (Moderna) | 18,686,366 | 113,724 | 32.4 (32.2–32.6) | 17,575,605 | 1853 | 0.56 (0.54–0.59) |
| Ad26. COV2.S (Janssen-Johnson & Johnson) | 3,876,768 | 50,886 | 79.0 (78.3–79.7) | 3,646,431 | 768 | 1.27 (1.18–1.36) |
| Vaccine product and recipient age — yr | ||||||
| BNT162b2 | ||||||
| 12–17 | 2,253,130 | 8974 | 39.3 (38.5–40.1) | 2,119,998 | 1 | 0 (0–0.03)† |
| 18–49 | 11,066,415 | 114,320 | 62.7 (62.4–63.1) | 10,480,750 | 59 | 0.03 (0.03–0.04) |
| 50–64 | 6,570,353 | 59,439 | 50.0 (49.6–50.4) | 6,196,382 | 334 | 0.30 (0.27–0.33) |
| 65–79 | 4,936,528 | 46,591 | 43.2 (42.8–43.6) | 4,617,760 | 1307 | 1.30 (1.23–1.37) |
| ≥80 | 1,442,739 | 17,727 | 52.8 (52.1–53.6) | 1,351,425 | 2000 | 6.36 (6.08–6.64) |
| mRNA-1273 | ||||||
| 18–49 | 6,901,002 | 47,468 | 41.3 (41.0–41.7) | 6,495,495 | 41 | 0.04 (0.03–0.05) |
| 50–64 | 5,077,105 | 27,701 | 30.6 (30.2–30.9) | 4,779,322 | 211 | 0.25 (0.22–0.28) |
| 65–79 | 5,189,360 | 28,523 | 25.6 (25.3–25.9) | 4,884,325 | 745 | 0.71 (0.66–0.76) |
| ≥80 | 1,518,899 | 10,032 | 29.6 (29.0–30.1) | 1,416,463 | 856 | 2.71 (2.53–2.90) |
| Ad26.COV2.S | ||||||
| 18–49 | 2,055,132 | 27,481 | 85.3 (84.3–86.3) | 1,931,126 | 34 | 0.11 (0.08–0.16) |
| 50–64 | 1,205,901 | 16,356 | 77.6 (76.5–78.8) | 1,123,416 | 196 | 1.00 (0.87–1.15) |
| 65–79 | 488,844 | 5552 | 62.6 (61.0–64.3) | 469,317 | 319 | 3.74 (3.35–4.17) |
| ≥80 | 126,891 | 1497 | 65.2 (62.0–68.6) | 122,572 | 219 | 9.86 (8.63–11.25) |
| Vaccination cohort | ||||||
| January to February | 8,366,983 | 114,195 | 50.1 (49.8–50.4) | 7,863,667 | 2692 | 1.26 (1.21–1.3) |
| March to April | 24,331,245 | 216,897 | 46.0 (45.8–46.2) | 22,755,728 | 3035 | 0.69 (0.66–0.71) |
| May to June | 13,565,104 | 72,812 | 43.2 (42.9–43.5) | 12,905,249 | 524 | 0.33 (0.30–0.36) |
| July | 2,568,967 | 7757 | 58.9 (57.6–60.2) | 2,463,707 | 71 | 0.56 (0.45–0.71) |
| Region‡ | ||||||
| South | 17,665,391 | 212,064 | 66.3 (66.0–66.6) | 17,665,391 | 4396 | 1.37 (1.33–1.42) |
| West | 6,201,697 | 48,334 | 42.2 (41.8–42.6) | 6,201,697 | 436 | 0.38 (0.35–0.42) |
| Northeast | 13,657,121 | 74,163 | 31.4 (31.1–31.6) | 13,657,121 | 653 | 0.28 (0.26–0.30) |
| Midwest | 11,308,090 | 77,100 | 36.8 (36.5–37.0) | 8,464,142 | 837 | 0.53 (0.50–0.57) |
Rates are calculated using person-weeks as the denominator, and 95% confidence intervals are provided in parentheses. The widths of the intervals have not been adjusted for multiplicity and any of the inferences drawn may not be reproducible. Wisconsin did not contribute deaths due to lack of linkage between vital records and COVID-19 case surveillance.
Rates for counts fewer than 15 may be unstable and should be interpreted with caution.
Regions comprise the following jurisdictions: South (Arkansas, Georgia, Florida, and Tennessee), West (Arizona, Idaho, New Mexico, and Utah), Northeast (Massachusetts, New Jersey, and New York City), and Midwest (Indiana, Michigan, Nebraska, and Wisconsin).